In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy

However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial 

Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials 

Long-term data from monarchE supports dose reduction while NATALEE data reinforces consistency across subgroups

Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors

Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed 

Encouraging preliminary results are reported with innovative antibody–drug conjugate designs, but underlying mechanisms of action still need to be described to improve efficacy and tolerability 

Disappointing results were reported from the phase III MANTRA trial, but biomarker-based approaches still offer hope for MDM2 inhibition in solid tumours 

In the DESTINY-PanTumour01 trial, promising response rates were seen with trastuzumab deruxtecan in heavily pre-treated patients with different cancer types

Study findings support routine RET-mutation testing for all patients with advanced MTC, but further work is needed to identify predictive markers